What they should’ve done, imo, is not give up on the successful heart, liver, etc.. trials that we finished up the end of last year.
They basically dropped everything they’d been doing when they acquired Rio’s stuff.
Maybe I’m wrong, but I think there was WAY more potential with “our” device, than there is with SofPulse.
But clearly they either don’t think that way, or something is going on that they haven’t told shareholders about. I guess it could be a money issue, too.
News 
Market Data 
Discover 
